Lidia Bermudez, MD
Adult Medicine · Hialeah, FLNPI 1730250663
Payments from drug & device makers
Across 225 payments — averaging $11,401 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organon$2M
- Genentech, Inc.$220K
- Eli Lilly$185K
- AstraZeneca$56K
- Ionis Pharmaceuticals, Inc.$55K
- Sumitomo Pharma America, Inc.$21K
- plus $68K from 17 others
Across 2 payments — averaging $22,393 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$45K
What the payments were for
- Food & beverage$419100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organon | 139 | $1,960,323 |
| Genentech, Inc. | 25 | $219,882 |
| Eli Lilly | 6 | $184,700 |
| AstraZeneca | 8 | $56,233 |
| Ionis Pharmaceuticals, Inc. | 3 | $55,337 |
| Sumitomo Pharma America, Inc. | 6 | $21,036 |
| Boehringer Ingelheim International GmbH | 16 | $17,186 |
| Janssen Research & Development, LLC | 1 | $14,370 |
| Chiesi USA, Inc. | 2 | $13,795 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $8,900 |
| Pfizer | 2 | $5,243 |
| GSK | 1 | $4,500 |
| E.r. Squibb & Sons, L.L.C. | 1 | $1,978 |
| H. Lundbeck A S | 1 | $1,444 |
| Amgen | 3 | $62 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $57 |
| Hologic Sales And Service, LLC | 2 | $53 |
| Astellas Pharma US Inc | 1 | $32 |
| Novartis | 1 | $28 |
| Abbott | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Sunovion Pharmaceuticals Inc. | 1 | $22 |
| AbbVie | 1 | $22 |
How this compares
$2,565,249 in reported general payments places this provider in the 95th percentile of 195 adult medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 665 | $393,818 |
| JanuviaSitagliptin Phosphate | 132 | $100,528 |
| LinzessLinaclotide | 170 | $89,199 |
| EntrestoSacubitril/Valsartan | 124 | $82,849 |
| FarxigaDapagliflozin Propanediol | 98 | $73,805 |
| XareltoRivaroxaban | 92 | $66,811 |
| OzempicSemaglutide | 65 | $64,667 |
| JardianceEmpagliflozin | 80 | $53,258 |
| MounjaroTirzepatide | 38 | $48,749 |
| Megestrol Acetate | 437 | $37,596 |
| TradjentaLinagliptin | 46 | $35,184 |
| RestasisCyclosporine | 51 | $32,883 |
| SantylCollagenase Clostridium Hist. | 69 | $26,394 |
| SsdSilver Sulfadiazine | 763 | $26,225 |
| Memantine Hcl | 694 | $26,144 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $5,243 | $393,818665 claims |
| AbbVieLinzess, Restasis | $22 | $122,081221 claims |
| AstraZenecaFarxiga, Brilinta, Symbicort | $56,233 | $96,761157 claims |
| NovartisEntresto | $28 | $82,849124 claims |
| GSKBreo Ellipta | $4,500 | $24,68751 claims |
| Astellas Pharma US IncMyrbetriq | $32 | $17,84838 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 195 adult medicine providers in Florida.
Other adult medicine in Hialeah
- Orlando MorenoHialeah$149K
- Esperanza Arce NunezHialeah$130K
- Juan BarrosoHialeah$4K
- Hernando AlvarezHialeah$4K
- Lucky FloresMiami Lakes$4.2M
- Linda MartinezDoral$2.1M
- Nelson GonzalezMiami$1.6M
- Victor SilvaTampa$1.2M
- Francisco Gonzalez AbreuMiami$774K
- Maria de la TorreMiami$685K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.